Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Sang Yu

Showing results (281-290 of 349) with videos related to

Pageof 35
Sort By:
Therapeutic Drug Monitoring|May 14, 2013
Population pharmacokinetics of theophylline in premature Korean infantsSung Eun Kim, Bo-Hyung Kim, Seunghwan Lee, et al.
Clinical Drug Investigation|March 14, 2014
Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agentHyeKyung Han, Jongtae Lee, Donghoon Shin, et al.
Drug Design, Development and Therapy|October 23, 2014
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersNamyi Gu, Min Kyu Park, Tae-Eun Kim, et al.
Clinical Therapeutics|June 26, 2012
The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trialNamyi Gu, Bo-Hyung Kim, Kyoung Soo Lim, et al.
Journal of Cardiovascular Pharmacology|July 19, 2011
The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteersKwang-Hee Shin, Tae-Eun Kim, Sung Eun Kim, et al.
British Journal of Clinical Pharmacology|August 30, 2008
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjectsKyoung Soo Lim, Joo-Youn Cho, In-Jin Jang, et al.
British Journal of Clinical Pharmacology|November 27, 2008
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patientsJung-Ryul Kim, Hyo-Bum Seo, Joo-Youn Cho, et al.
American Journal of Physiology. Renal Physiology|March 25, 2011
In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathyJung Pyo Lee, Seung Hee Yang, Dong Ki Kim, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteersJae-Yong Chung, Joo-Youn Cho, Kyung-Sang Yu, et al.
Clinical Therapeutics|May 4, 2010
Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjectsKyoung Soo Lim, In-Jin Jang, Bo-Hyung Kim, et al.
Pageof 35

Showing results (281-290 of 349) with videos related to

Sort By:
Pageof 35
Therapeutic Drug Monitoring|May 14, 2013
Population pharmacokinetics of theophylline in premature Korean infantsSung Eun Kim, Bo-Hyung Kim, Seunghwan Lee, et al.
Clinical Drug Investigation|March 14, 2014
Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agentHyeKyung Han, Jongtae Lee, Donghoon Shin, et al.
Drug Design, Development and Therapy|October 23, 2014
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersNamyi Gu, Min Kyu Park, Tae-Eun Kim, et al.
Clinical Therapeutics|June 26, 2012
The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trialNamyi Gu, Bo-Hyung Kim, Kyoung Soo Lim, et al.
Journal of Cardiovascular Pharmacology|July 19, 2011
The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteersKwang-Hee Shin, Tae-Eun Kim, Sung Eun Kim, et al.
British Journal of Clinical Pharmacology|August 30, 2008
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjectsKyoung Soo Lim, Joo-Youn Cho, In-Jin Jang, et al.
British Journal of Clinical Pharmacology|November 27, 2008
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patientsJung-Ryul Kim, Hyo-Bum Seo, Joo-Youn Cho, et al.
American Journal of Physiology. Renal Physiology|March 25, 2011
In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathyJung Pyo Lee, Seung Hee Yang, Dong Ki Kim, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteersJae-Yong Chung, Joo-Youn Cho, Kyung-Sang Yu, et al.
Clinical Therapeutics|May 4, 2010
Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjectsKyoung Soo Lim, In-Jin Jang, Bo-Hyung Kim, et al.
Pageof 35